SS-31
SS-31 (Elamipretide / MTP-131)
A mitochondria-targeting peptide that reduces oxidative stress and improves mitochondrial function. In Phase 2/3 trials for heart failure.
SS-31 is not approved by the FDA for human use. It is sold strictly for research purposes only and is not intended for human consumption, diagnosis, treatment, or prevention of any disease or condition. Purchase and use is entirely at your own risk.
Sourcing for research purposes?
View at Ascension Peptides →What it is
SS-31 (Szeto-Schiller peptide 31), also known as Elamipretide or MTP-131, is a cell-permeable tetrapeptide that selectively targets the inner mitochondrial membrane. It works by binding to cardiolipin — a phospholipid critical for the electron transport chain — and reducing oxidative stress.
It has progressed further in formal clinical development than most peptides on this platform, with Phase 2/3 trials conducted in heart failure and Barth syndrome.
What research shows
- Reduces mitochondrial reactive oxygen species (ROS) without impairing ATP production
- Improved cardiac function in heart failure animal models and some human trials
- Benefit in Barth syndrome — a rare mitochondrial disease — in clinical trials
- Kidney protection in acute kidney injury models
- Reversal of age-related mitochondrial dysfunction in animal studies
What remains unknown
- Phase 3 heart failure trial results — mixed Phase 2 data means certainty is limited
- Optimal dosing in otherwise-healthy longevity-focused individuals
- Long-term safety profile outside of clinical trial settings
Administration basics
Common use cases
Mitochondrial health, longevity protocols, cardiovascular research.
Half-life
Short in plasma. Administered by subcutaneous infusion in trials.
Administration
Subcutaneous injection or infusion.
Source this compound
Looking for SS-31?
Ascension Peptides is a third-party research compound vendor. We link to them as an affiliate — if you purchase through our link we may earn a commission at no cost to you. All compounds are sold for research purposes only and are not intended for human use.
View at Ascension PeptidesResearch Protocols & Common Usage
Doses used in research
- Clinical studies have used 0.25mg/kg subcutaneously
- Community protocols vary significantly due to limited established human dosing
Administration routes studied
Typical protocol duration
Clinical trials have used protocols ranging from single doses to multi-week administration.
Common stacking protocols
- SS-31 + NAD+ precursors — combined for comprehensive mitochondrial support
- SS-31 + Methylene Blue — combined in some mitochondrial optimization protocols
Contraindications & combinations to avoid
- Limited human safety data — the full interaction profile is not established
- Heart failure patients should only use under physician supervision
Dosing information reflects doses used in published research and commonly reported community protocols only. This is not a personal recommendation. These compounds are not FDA-approved for human use in the contexts described. Consult a qualified healthcare provider before starting any protocol.
Considering stacking?
See the stacking guide for common combinations with SS-31 and what to avoid.
Track your SS-31 protocol
Log your experience, track outcomes over time, and get AI-powered interpretation of your results after 14 days of data. Private, $14.99/month.
Start trackingGet research updates
We'll notify you when we update the SS-31 page or publish related research.
More in the library
Community Reviews
Reviews reflect individual user experiences with research compounds and are not medical advice. Results vary. These compounds are not FDA approved for human use. Peptelligent does not verify reported experiences.
Write a Review
No reviews yet. Be the first to share your experience.